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doi:10.1016/j.numecd.2009.03.015Abstract Background and Aim: The role of Dipeptidyl Peptidase-4 (DPP-4) inhibitors in the
treatment of type 2 diabetes is debated; many recent trials, which were not included in
previous meta-analyses, could add relevant information.
Methods and Results: All available randomized controlled trials (RCTs), either published or
unpublished, performed in type 2 diabetic patients with DPP-4 inhibitors, with a duration
>12 weeks were meta-analyzed for HbA1c, BMI, hypoglycemia, and other adverse events.
A total of 41 RCTs (9 of which are unpublished) was retrieved and included in the analysis.
Gliptins determine a significant improvement of HbA1c in comparison with a placebo (0.7
[0.8:0.6]), with a low risk of hypoglycemia. DPP-4 inhibitors show a similar efficacy in
monotherapy and in combination with other agents. The risk of cardiovascular events and
all-cause death with DPP-4 inhibitors is 0.76 [0.46e1.28] and 0.78 [0.40e1.51], respectively.
Conclusions: DPP-4 inhibitors reduce HbA1c, although to a lesser extent than sulphonylureas,
with no weight gain and no hypoglycemic risk; further data are needed to assess their long-
term safety.
ª 2009 Elsevier B.V. All rights reserved.Introduction
Oral Dipeptidyl Peptidase-4 (DPP-4) inhibitors sitagliptin [1]
and vildagliptin [2], which increase circulating levels of
Glucagon-Like Peptide-1 (GLP-1), have recently beenucci, Department of Critical
icine, Azienda Ospedaliero-
te 4, 50141 Florence, Italy.
7949660.
nucci@unifi.it, mmonami@
9 Elsevier B.V. All rights reservedapproved for use in type 2 diabetes; other molecules of the
same class (such as saxagliptin and alogliptin) are under
development.
The role of those new drugs in the treatment of type 2
diabetes is debated. The consensus algorithm of the
American Diabetes Association and the European Associa-
tion for the Study of Diabetes [3,4], in its revised version
[4], suggests limiting the use of GLP-1 receptor agonists and
DPP-4 inhibitors only in some specific cases, without
considering those agents in the mainstream (‘‘Tier 1’’) of
the algorithm. Conversely, DPP-4 inhibitors are not even
included as a second choice, although their use is
contemplated in selected patients. The reasons for this.
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comparison with other agents, their poorly defined safety
profile, and their cost [3,4].
Efficacy and safety need to be assessed through
a comprehensive review of currently available clinical
trials. Some detailed reviews of published studies have
been recently published [1,2,5]; furthermore, some meta-
analyses have been performed [1,6e8]. However, currently
available meta-analyses included only published studies,
without any attempt at retrieving data from completed and
publicly disclosed, although not formally published, clinical
trials. Furthermore, several trials have been published in
the last few months, increasing in a relevant manner the
available data base for the assessment of the clinical profile
of DPP-4 inhibitors.
The aim of the present study is to offer a comprehensive
and updated synthesis of all available clinical data on the
safety and efficacy of DPP-4 inhibitors.Methods
A meta-analysis was performed including all randomized
clinical trials, either with a cross-over or a parallel series
design, enrolling patients with type 2 diabetes, with
a duration of at least 12 weeks, comparing Dipeptidyl
Peptidase-4 (DPP) inhibitors with a placebo or other active
drugs (oral hypoglycemic agents and/or insulin). Trials with
a shorter duration were excluded, due to the fact that they
could not yield relevant information on glycated hemo-
globin, which had been chosen as the principal outcome
variable. Trials enrolling nondiabetic, or type 1 diabetic,
subjects were also excluded.
An extensive Medline search for ‘‘vildagliptin’’, ‘‘sita-
gliptin’’, ‘‘saxagliptin’’, and ‘‘alogliptin’’ was performed,
collecting all randomized clinical trials on humans up to
November 11th, 2008. The identification of relevant
abstracts, the selection of studies based on the criteria
described above, and the subsequent data extraction were
performed independently by two of the authors (E.M.,
M.M.), and conflicts resolved by the third investigator
(N.M.). The quality of trials was assessed using some of the
parameters proposed by Jadad et al. [9]. The score was not
used as a criterion for the selection of trials, whereas some
items were used only for descriptive purposes.
Completed but still unpublished trials were iden-
tified through a search of www.clinicaltrials.gov web-
site. Results of those trials were retrieved, if available,
on www.merck.com/mrl/clinical_trials/results.html, www.
novartisclinicaltrials.com, or www.clinicalstudyresults.org.
The principal outcome was the effect of DPP-4 inhibi-
tors, compared with other hypoglycemic agents or
a placebo, on HbA1c at the end of trial. Secondary
outcomes included body mass index (BMI) at the end of the
trial. Furthermore, data on the incidence of severe
(requiring help from other persons) or any hypoglycemia
(number of patients with at least one event) and several
adverse events were extracted. The following adverse
events were considered: any adverse event, nausea, vom-
iting, diarrhea, nasopharyngitis, upper respiratory tract
infections, lower urinary tract infections and other infec-
tions. Furthermore, cases of pancreatitis, angioedema andcardiovascular events (defined as myocardial infarction,
angina pectoris, coronary artery revascularization, chronic
heart failure, stroke and arteriopathy of lower limbs)
reported as serious or severe adverse events were consid-
ered, together with death from any cause. The choice of
adverse events considered as endpoints was based on
reported drug-specific adverse effects of DPP-4 inhibitors
and/or other incretin-based therapies [6]. Microvascular
complications of diabetes were not considered due to the
relatively short duration of the trials included in the meta-
analysis.
Separate analyses were performed for trials with
different DPP-4 inhibitors, whenever possible.
Heterogeneity was assessed by using I2 statistics. If a low
heterogeneity was detected we applied both a random-
effects and a fixed-effects model. We report the results of
the random-effects models [10] because the validity of tests
of heterogeneity can be limited with a small number of
component studies. To estimate possible publication bias
caused by the tendency of published studies to be positive,
we used funnel plots, the Begg adjusted rank correlation test
[11], and the Egger regression approach [12], including only
published trials. However, because these tests have low
statistical power when the number of trials is small [13],
undetected bias may still be present. Weighted mean
differences were calculated for HbA1c and BMI and a random
effect model was used for the meta-analysis. Mantele
Haenszel odds ratio (MH-OR) with 95% Confidence Interval
was calculated for hypoglycemia, and the adverse events
defined above, on an intention-to-treat basis, using
a random effect model, excluding trials with zero events. All
analyses were performed using Comprehensive Meta-anal-
ysis Version 2, Biostat (Englewood, NJ, USA) and SPSS 16.0.
Results
The trial flow is summarized in Fig. 1, and the character-
istics of the trials included in the meta-analysis are
summarized in Table 1. Among the trials included, 32 were
described in publications in peer-reviewed journals; results
of 9 unpublished trials were disclosed on different web-
sites. Furthermore, 10 unpublished trials, the results of
which were undisclosed, could be identified (Table 2).
Notably, results could be retrieved for the large majority of
trials on currently available DPP-4 inhibitors (sitagliptin and
vildagliptin), while only results of preliminary phase II
studies were available for products currently under devel-
opment (saxagliptin).
The Begg adjusted rank correlation test (Kendall tau:
74; pZ 0.13) and the Egger regression approach (inter-
cept, 2.81 [CI, e6.91e1.27]) suggested no major publi-
cation bias.
Efficacy
The metabolic effects of DPP-4 inhibitors observed in clin-
ical trials included in the meta-analysis are summarized in
Table 3. I2 for heterogeneity on HbA1c was 94.6 (p< 0.01).
Both sitagliptin and vildagliptin produced a significant
reduction of HbA1c in placebo-controlled trials (Fig. 2);
a separate analysis was not performed for saxagliptin, for
PUBLISHED TRIALS
(Medline search)
Retrieved
n=602
INCLUDED
n=32
Duplicate publications
n=19
Not on humans
n=50
Not RCT
n=397
Excluded for:
UNPUBLISHED
TRIALS
Retrieved
n=99
INCLUDED
n=9
Duration<12 weeks
n=18
Ongoing
n=11
Non diabetic patients
n=8
Not RCT
n=12
Excluded for:
Interrupted
n=1
TOTAL
n=41
Nondiabetic patients
n=49
Published
n=30
Undisclosed
n=10
Duration<12 weeks
n=55
Figure 1 Trial flow diagram. RCT: randomized clinical trial.
226 M. Monami et al.which only one trial was available. Similar reductions of
HbA1c, in comparison with a placebo, were observed in
monotherapy and in combination with other hypoglycemic
agents. The extent of HbA1c reduction was similar in
shorter and longer-term trials; similar effects of HbA1c
reduction were observed in placebo-controlled studies
enrolling patients with a different duration of diabetes or
baseline HbA1c (Fig. 2). The reduction of HbA1c in unpub-
lished trials (0.68 [1.57; 0.21]; pZ 0.13) was similar to
that obtained in published trials (0.70 [0.80; 0.59];
p< 0.001), although it did not reach statistical significance
due to the small number of unpublished studies (NZ 4). A
nonsignificant trend toward a greater placebo-subtracted
effect on HbA1c was observed in trials enrolling patients
with a mean baseline HbA1c lower than 8%, in comparison
with trials on subjects with a greater degree of hypergly-
cemia (Fig. 2). In active-comparator studies, DPP-4 inhibi-
tors showed a similar effect to that of thiazolidinediones;
conversely, in the two available direct comparison studies,
endpoint HbA1c with DPP-4 inhibitors (sitagliptin in both
cases) were higher than with sulfonylureas; similarly,metformin appeared to be more effective than DPP-4
inhibitors (Fig. 2). A meta-analysis of trials versus acarbose
could not be performed because only one trial was avail-
able. None of the trials with DPP-4 inhibitors reported 2-h
post-prandial glucose from home self-monitoring.
Body weight
DPP-4 inhibitors showed no significant effect on BMI in
placebo-controlled trials (þ0.2 [0.1; 0.6] kg/m2; pZ 0.11;
13 trials), while a modest, although significant, difference
was detected in comparison with thiazolidinediones (0.2
[0.3; 0.1] kg/m2; pZ 0.008). Comparisons with other
classes of hypoglycemic agents could not be meta-analyzed
due to the fact that BMI at endpoint was reported only in one
trial versus acarbose, sulfonylureas or metformin.
Safety: hypoglycemia
Information on hypoglycemia could be retrieved for 15 out
of 18 trials with sitagliptin, and 19 out of 21 with
Table 1 Characteristics of the studies included in the meta-analysis.
Study (Ref.) Dose
(mg/die)
Comparator Add-on to Description
of randomization
Description
of blinding
Reporting of
drop-out
Intention-to-treat
Vildagliptin
Pan [33] 100 Acarbose None NA NA A Yes
Schweizer [28] 100 Metformin None NA NA A Yes
Rosenstock [34] 50e100 Rosiglitazone None NA NA A Yes
2329 [14] 50e100 Pioglitazone None NR NR NR Yes
Bolli [21] 100 Pioglitazone Metformin NA NA A No
Rosenstock [35] 100 Pioglitazone None NA A A Yes
50e100 Placebo Pioglitazone NA A A Yes
Dejager [36] 50e100 Placebo None NA NA A Yes
Scherbaum [37] 50 Placebo None NA NA A Yes
Mari [38] 50 Placebo None NA NA A NR
Scherbaum [39] 50 Placebo None NA NA A Yes
Pratley [27] 50 Placebo None NA A A Yes
Pi-Sunyer [40] 50e100 Placebo None NA NA A Yes
Ristic [41] 25e100 Placebo None NA NA NA Yes
1202 [14] 20e100 Placebo None NR NR NR Yes
Ahren [42] 50 Placebo Metformin NA NA A NR
Bosi [22] 50e100 Placebo Metformin NA NA A Yes
Garber [43] 50e100 Placebo Pioglitazone NA NA A Yes
Garber [19] 50e100 Placebo Glimepiride A NA A Yes
1302 [14] 100 Placebo Glimepiride NR NR NR Yes
Fonseca [20] 100 Placebo Insulin NA NA A Yes
1303 [14] 50e100 Placebo NR NR NR NR Yes
D’Alessio [44] 100 Placebo Metf./None NA NA A Yes
Sitagliptin
PN-036 [15] 50e100 Metformin None NA A A Yes
Scott [45] 100 Rosiglitazone Metformin NA NA A Yes
100 Placebo Metformin NA NA A Yes
PN-035 [15] 100 Pioglitazone GlimMet NA NA A Yes
Nauck [17] 100 Glipizide Metformin NA NA A Yes
PN-028 [15] 25e50 Placebo/Glip. OAD/Insulin NR NR NR Yes
Scott [18] 10e100 Glipizide None A A A Yes
10e100 Placebo None A A A Yes
Nonaka [46] 100 Placebo None NA NA A Yes
Hanefeld [16] 25e100 Placebo None NA A A No
Raz [47] 100e200 Placebo None NA NA A Yes
Goldstein [23] 50e100 Placebo None NA A A Yes
Rosenstock [35] 100 Placebo Pioglitazone NA NA A Yes
Hermansen [24] 100 Placebo GlimMetf NA NA A Yes
Goldstein [23] 50e100 Placebo Metformin NA A A Yes
Charbonnel [48] 100 Placebo Metformin NA NA A Yes
Aschner [49] 100e200 Placebo None NA NA A Yes
Raz [50] 100 Placebo Metformin A NA A Yes
PN-040 [15] 100 Placebo OAD/None NR NR NR Yes
PN-044 [15] 25e200 Placebo OAD/None NR NR NR Yes
Saxagliptin
Rosenstock [51] 2.5e40 Placebo None NA NA A Yes
NA: not adequate or not adequately reported; A: adequate; NR: not reported; glip.: glipizide; glimmetf: glimepiride and/or
metformin; metf.: metformin; OAD: oral antidiabetic drugs; and SU/metf: sulfonylureas or metformin.
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[15], PN-036 [15], and PN-044 [15]), the overall number of
hypoglycemic episodes was not reported. Of the remaining
34 studies, 5 (2 with sitagliptin and 3 with vildagliptin)
reported that no hypoglycemic event had occurred during
the trial. In the remaining studies, hypoglycemia was
observed in 184 of 9944 patients treated with DPP-4inhibitors (103 of 4573, 81 of 5100, and 0 of 271 with sita-
gliptin, vildagliptin and saxagliptin, respectively) and 293
of 5698 in comparator groups. The incidence of hypogly-
cemia with DPP-4 inhibitors (both sitagliptin and vilda-
gliptin) was not significantly different from that observed
with a placebo, even when those agents were used in
combination with sulphonylureas or insulin (Fig. 3). In
Table 2 Characteristics of the unpublished and undisclosed studies.
Study # Patients planned Comparator Add-on to Trial duration (weeks) Design Randomization Study end datea
DPP-4 inhibitors
Vildagliptin
NCT00368134 [52] 370 Voglibose None 12 PS Double blind June 2007
NCT00396227 [52] 2665 Glitazones Metformin 12 PS Open label October 2007
Sitagliptin
NCT00411554 [52] 310 Voglibose None 12 PS Double blind August 2007
Saxagliptin
NCT00327015 [52] 1396 Placebo Metformin 52 PS Double blind November 2007
Metformin None 52 PS Double blind
NCT00121641 [52] 460 Placebo None 24 PS Double blind August 2007
NCT00374907 [52] 36 Placebo None 12 PS Double blind October 2007
NCT00295633 [52] 555 Placebo Glitazones 24 PS Double blind October 2007
NCT00121667 [52] 720 Placebo Metformin 24 PS Double blind August 2006
NCT00313313 [52] 780 Placebo Glyburide 24 PS Double blind September 2007
NCT00316082 [52] 365 Placebo None 24 PS Double blind November 2007
PS: parallel series.
a Final data collection date for primary outcome measure.
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a significantly lower hypoglycemic risk than sulphonylureas,
whereas no significant differences were detected with
respect to thiazolidinediones (Fig. 3). The number needed
to harm (NNH) for sulphonylureas in comparison with DPP-4
inhibitors, with respect to hypoglycemia, on an yearly
basis, was 128.
All trials with DPP-4 inhibitors reported information on
severe hypoglycemia, except 10 (6 with sitagliptin, 4 with
vildagliptin). In three distinct trials [16e18], severe hypo-
glycemia was reported by 5 patients treated with sitagliptin,
in monotherapy (NZ 4) or in combination with metformin
(NZ 1), versus 9 cases in comparator groups (all treated
with sulphonylureas). No case of severe hypoglycemia was
reported in patients treated with vildagliptin, versus 5 with
comparator (placebo in all cases); the severe hypoglycemic
episodes detected in vildagliptin trials occurred in combi-
nation studies with sulphonylureas [19] or insulin [20].
Safety: other adverse events
The proportion of patients experiencing any adverse event
was retrieved for 29 placebo-controlled trials and 11 active-
comparator study. Treatment with DPP-4 was not associ-
ated with any increase in the overall risk of adverse events
in comparison with placebo (MH-OR 1.03 [0.93; 1.13];
pZ 0.51) or thiazolidinediones (0.97 [0.81; 1.17]; pZ 0.75,
NZ 5 trials), whereas the incidence was significantly lower
than with sulphonylureas (0.64 [0.51; 0.80]; p< 0.001,
NZ 2 trials), metformin (0.78 [0.61; 1.00]; pZ 0.050,
NZ 2 trials), and a-glucosidase inhibitors (0.51 [0.39;
0.67]; p< 0.001, NZ 2 trials).
Information on mortality was unavailable for two vilda-
gliptin trials; at least one death was observed in 17 of the
remaining 39 trials with DPP-4 inhibitors. In those, 18 and
13 deaths were recorded in patients treated with the
investigational drug or with comparators, respectively
(Table 4). The risk of death with DPP-4 inhibitors, compared
with control groups, was 0.78 [0.40; 1.51]; pZ 0.47.Forty-one patients reported a cardiovascular event in
trials with DPP-4 inhibitors (Table 4). The MH-OR for
cardiovascular events, in comparison with control groups,
was 0.76 [0.46e1.28], pZ 0.30, for DPP-4 inhibitors; the
corresponding figure for placebo-controlled trials was 0.86
[0.47e1.59], pZ 0.63.
The other serious/severe adverse events considered
occurred in only a few cases, preventing any statistical
analysis. In all the trials included, two cases of pancreatitis
were reported (1 during vildagliptin and 1 with placebo),
along with 6 cases of angioedema (3 with vildagliptin, 1
with sitagliptin, and 2 with placebo).
Other adverse events are reported in Table 4. No
increase of gastrointestinal adverse events was detected
with DPP-4 inhibitors. A significant increase in the risk of
nasopharyngitis was observed with sitagliptin (NNHZ 98),
but not with vildagliptin, while a nonsignificant trend
toward the increase of risk of urinary tract infection was
observed with vildagliptin only. Treatment with DPP-4
inhibitors was not associated with any increase in the risk of
upper respiratory tract infections, different from naso-
pharyngitis, whereas the actual incidence of other infec-
tions was lower than in comparator groups (Table 5).
Discussion
DPP-4 inhibitors have been proposed as an alternative to
currently available therapies (sulphonylureas, thiazolidi-
nediones or insulin), mainly as an add-on treatment in
patients failing with metformin monotherapy. However,
even the most recent version of the ADAeEASD consensus
algorithm does not consider these drugs a viable option,
except for selected cases [4]. The reasons for exclusion
from the main treatment algorithm are scarce efficacy,
limited amount of available evidence and high cost. With
respect to available evidence, it should be recognized that
several trials, which had not been included in previous
meta-analyses [6], have been recently published [19,21e
25]. Furthermore, there are a relevant number of
Table 3 Moderators and outcome variables in individual studies included in the meta-analysis.
Study (Ref.) # Patients
(ID/C)
Comparator Trial duration
(weeks)
>Agea
(years)
Duration
of DMa
(years)
HbA1c
baselinea
(%)
HbA1c
endpoint
(%, ID/C)
BMI
baselinea
(Kg/m2)
BMI endpoint
(Kg/m2)
DPP-4 inhibitors
Vildagliptin
Pan [33] 440/220 Acarbose 24 52 1.2 8.6 7.2/7.3 26.1 26.3/25.2
Schweizer [28] 526/254 Metformin 52 53 1.0 8.7 7.7/7.3 32.4 32.5/31.8
Rosenstock [34] 459/238 Rosiglitazone 24 54 2.5 8.7 7.6/7.4 32.5 32.1/33.5
2329 [14] 218/55 Pioglitazone 12 52 2.0 10.0 NR NR NR
Bolli [21] 295/280 Pioglitazone 24 56 6.4 8.4 7.5/7.5 32.1 32.1/32.8
Rosenstock [35] 154/161 Pioglitazone 24 51 2.0 8.7 7.0/7.3 29.4 29.9/29.4
292/161 Placebo 24 52 2.0 8.7 7.5/7.3 29.3 29.5/29.4
Dejager [36] 472/160 Placebo 24 54 2.1 8.4 7.6/8.1 32.9 NR
Scherbaum [37] 67/61 Placebo 52 64 3.3 6.6 6.6/7.1 30.2 NR
Mari [38] 156/150 Placebo 52 63 2.6 6.7 6.5/6.9 30.2 NR
Scherbaum [39] 156/150 Placebo 52 63 2.5 6.7 6.5/6.9 30.2 30.2/29.9
Pratley [27] 70/28 Placebo 12 55 4.0 8.0 7.4/8.1 29.9 NR
Pi-Sunyer [40] 262/92 Placebo 24 51 2.1 8.4 7.7/8.4 32.2 31.9/32.2
Ristic [41] 221/58 Placebo 12 56 3.0 7.7 7.2/7.7 31.1 31.0/31.4
1202 [14] 219/72 Placebo 12 59 NR 7.4 6.7/7. 24.0 NR
Ahren [42] 56/51 Placebo 12 57 5.5 7.8 7.1/7.8 29.7 NR
Bosi [22] 349/171 Placebo 24 54 6.2 8.4 7.5/8.4 32.7 32.5/31.7
Garber [43] 260/138 Placebo 24 54 4.7 8.7 7.6/8.1 32.4 NR
Garber [19] 264/144 Placebo 16 58 7.1 8.5 7.9/8.6 31.4 31.8/31.2
1302 102/100 Placebo 12 60 9.0 7.9 6.8/7.9 NR NR
Fonseca [20] 144/152 Placebo 24 59 14.7 8.4 7.9/8.2 33.1 33.8/33.1
1303 [14] 178/61 Placebo 12 60 6.5 7.4 6.5/7.7 NR NR
D’Alessio [44] 20/19 Placebo 12 55 3.5 6.7 6.3/6.3 32.3 NR
Sitagliptin
PN-036 [15] 179/176 Metformin 30 53 4.5 8.9 8.1/7.6 31.9 NR
Scott [45] 94/87 Rosiglitazone 18 55 5.0 7.7 7.0/6.9 30.2 30.1/30.9
94/92 Placebo 18 55 5.0 7.7 7.0/7.5 30.1 30.1/29.8
PN-035 [15] 91/68 Pioglitazone 30 56 8.7 8.2 7.6/8.0 31.2 NR
Nauck [17] 576/559 Glipizide 52 57 6.3 7.7 7.2/7.0 31.2 30.7/31.7
PN-028 [15] 65/26 Placebo/Glip 54 68 13.5 7.7 7.0/7.6 NR NR
Scott [18] 595/123 Glipizide 12 55 5.0 7.9 7.5/7.1 30.8 NR
595/125 Placebo 12 55 5.0 7.9 7.5/8.1 31.0 NR
Nonaka [46] 75/76 Placebo 12 55 4.0 7.6 6.9/8.1 25.2 NR
Hanefeld [16] 444/111 Placebo 12 56 3.7 7.7 7.4/7.8 31.7 NR
Raz [47] 411/110 Placebo 18 55 4.6 8.0 7.7/8.2 32.1 31.8/32.3
Goldstein [23] 179/176 Placebo 24 53 4.5 8.7 8.2/8.9 31.9 NR
Rosenstock [35] 175/178 Placebo 24 56 6.1 8.1 7.2/7.8 31.5 32.6/31.5
Hermansen [24] 222/219 Placebo 24 56 8.7 8.3 7.8/8.6 31.0 31.5/31.2
Goldstein [23] 372/364 Placebo 54 53 4.4 8.8 7.1/7.8 32.2 NR
Charbonnel [48] 429/206 Placebo 24 54 6.3 8.0 7.3/7.9 31.3 NR
Aschner [49] 488/253 Placebo 24 54 4.4 8.0 7.3/8.2 30.5 30.3/30.5
Raz [50] 96/94 Placebo 30 55 8.0 9.2 8.3/9.1 30.2 NR
PN-040 [15] 352/178 Placebo 18 NR NR 8.7 NR NR NR
PN-044 [15] 290/73 Placebo 12 NR NR 7.6 NR NR NR
Saxagliptin
Rosenstock [51] 271/67 Placebo 12 53 1.0 7.9 7.1/7.7 31.0 30.7/30.7
ID/C: investigational drug/comparator; DM: diabetes mellitus; and glip.: glipizide.
a Mean values.
DPP-4 inhibitors and type 2 diabetes 229unpublished trials, the results of which have been disclosed
on different websites, and are therefore available. The
decision to publish a trial is, in most instances, performed
by the sponsor which has a specific interest in pursuing thegreater safety and tolerability of the new drug. This bias is
unfortunate and limits the reliability of this and other
meta-analysis, often based only on data provided from
manufacturers; however, the retrieval of all available
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Figure 2 Standardized differences (with 95% CI) of mean HbA1c at endpoint.
230 M. Monami et al.information should always be attempted, although the
possibility of including some information of poorer meth-
odological quality should be taken into account. The overall
amount of evidence from randomized clinical trials which
can be retrieved using this comprehensive approach is
relevant, and probably sufficient for a reliable assessment
of the clinical profile of this new class.
The overall efficacy on HbA1c of DPP-4 inhibitors in
placebo-controlled trials is similar to that reported in
previous meta-analyses [1,6e8]. However, the greater
number of available studies allowed separate analyses of
trials in which DPP-4 inhibitors were used either as0.01
Mant
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Figure 3 ManteleHaenszel odds ratio (with 95%monotherapy or as an add-on to other agents. In fact, most
currently available hypoglycemic treatments show a smaller
additional effect on HbA1c when used as an add-on to
metformin, in comparison with monotherapy trials [26].
Conversely, DPP-4 inhibitors produce a similar placebo-
subtracted reduction of HbA1c either in monotherapy or as
an add-on to other agents. This pattern resembles that of
other drugs specifically active on post-prandial glucose, such
as acarbose or glinides [26]. In fact, DPP-4 inhibitors, as well
as GLP-1 receptor agonists, show a relevant effect on post-
prandial hyperglycemia. Although data on post-prandial
glucose measured through self-monitoring were not0.10 1.0 10.0
el Haenzel Odds Ratio (95%CI)
CI) for any hypoglycemia (logarithmic scale).
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[7,27] support the hypothesis of a specific action of DPP-4
inhibitors on post-prandial hyperglycemia.
Based on the considerations reported above, DPP-4
inhibitors, when used in combination with other drugs,
should not be expected to be less effective on HbA1c than
other agents (such as sulphonylureas, thiazolidinediones or
insulin). Unfortunately, only a small number of head-to-
head comparisons with other drugs are currently available.
The efficacy of DPP-4 inhibitors on HbA1c, either in mon-
otherapy or in combination with metformin, appears to be
somewhat smaller than that of sulphonylureas, and similar
to thiazolidinediones; the only two available comparisons
with metformin, both in monotherapy, one with vildagliptin
[28] and one with sitagliptin (PN-036 on www.merck.com/
mrl/clinical_trials/results.html) suggest a smaller effect
on HbA1c. It should be considered that most trials are of
a relatively short duration and it is possible that sulpho-
nylureas, which are known to produce a less durable effect
on glucose than other available agents, [29] could provide
less favorable results in the long-term.
Taken together, the present results on efficacy do not
support the use of DPP-4 inhibitors in monotherapy as an
alternative to metformin. On the other hand, these drugs
appear to be effective as add-on treatments in patients
failing with metformin monotherapy, with a specific effect
on post-prandial glucose, although the short-term efficacy
of sulphonylureas on HbA1c could be greater than that of
DPP-4 inhibitors.
With respect to body mass index, this meta-analysis
confirms the neutrality of DPP-4 inhibitors [1,6e8]. In direct
comparison, DPP-4 inhibitors appear to have an advantage
in this respect over thiazolidinediones.
GLP-1 stimulates insulin secretion and inhibits glucagon
production in a glucose-dependent manner, i.e. its effects
are blunted when blood glucose reaches the lower limits of
the normal range [30]. Therefore, DPP-4 inhibitors are
expected to reduce glycemia with a low hypoglycemic risk.
In fact, DPP-4 inhibitors do not induce any additional risk, in
comparison with a placebo, either in monotherapy or in
combination with sulphonylureas or insulin. This confirms
the results of a recent meta-analysis performed on patient-
level data from randomized clinical trials with sitagliptin
[31]. Interestingly, in the only trial performed in insulin-
treated patients, vildagliptin reduced the incidence of
hypoglycemia in comparison with a placebo [20]. The
mechanisms underlying this phenomenon need to be further
elucidated. As expected, DPP-4 inhibitors do not increase
the incidence of hypoglycemic episodes when compared
with insulin-sensitizing drugs; on the other hand, they show
a markedly reduced risk of hypoglycemia in head-to-head
comparisons with sulphonylureas. This difference, which
could be partly determined by a marginally greater efficacy
of sulphonylureas on HbA1c, is consistent with the different
mechanisms of action of the classes of drugs.
No patient experienced severe hypoglycemia during
vildagliptin therapy. Unexpectedly, episodes of severe
hypoglycemia occurred in five patients treated with sita-
gliptin, either in monotherapy or in combination with
metformin, in three different trials [16e18]. Notably, two
of those trials [16,18], although published, did not report
those events but since those trials were included in theregistration data for drug approval in the US, the informa-
tion on severe hypoglycemia can be retrieved from the FDA
website. Furthermore, episodes of severe hypoglycemia
were not considered in a recent meta-analysis of trials with
sitagliptin, although a greater number of such events had
occurred in comparator groups, which included sulphony-
lureas [31]. It should also be considered that some of the
trials did not report any information on severe hypogly-
cemia, raising the possibility of a selective reporting bias.
The occurrence of cases of severe hypoglycemia with DPP-4
inhibitor monotherapy is difficult to explain on the basis of
the current knowledge of the mechanism of action of those
drugs, and deserved further investigation.
Among other expected adverse events, the previously
reported increased incidence of some infections during
DPP-4 inhibitor therapy [6,8] is confirmed, with sitagliptin,
but not vildagliptin, associated with nasopharyngitis, and
with a nonsignificant trend toward an increased risk of
urinary tract infections. These results are consistent with
those of a recent meta-analysis on patient-level data from
trials with sitagliptin, which included only a fraction of the
studies summarized in the present meta-analysis, and
which showed a similar trend toward the increase of risk of
nasopharyngitis with the DPP-4 inhibitor, although it failed
to reach statistical significance [31]. It should be consid-
ered that DPP-4 is involved in the interaction between
immune cells and that it could therefore modulate immune
responses [32]; however, there is no evidence from mech-
anistic studies that inhibition of DPP-4 with currently
available agents has an immunodepressant effect. Consis-
tently, treatment with DPP-4 inhibitors does not appear to
increase the risk of infections other than nasopharyngitis
and urinary tract infections.
The introduction of a new class of drugs which are
designed for long-term use always raises some concerns
about safety during prolonged treatment. The possibility
of rare, unexpected serious adverse events, which could
not be detected in registration trials, should be consid-
ered. The number of reported deaths in available trials is
still very small; however, there is no evidence suggesting
an increase in mortality during treatment with DPP-4
inhibitors. The number of cardiovascular events regis-
tered in clinical trials is remarkably greater, although still
inadequate to detect minor differences between groups.
The two drugs which have been more thoroughly studied
(sitagliptin and vildagliptin) do not seem to be associated
with increased cardiovascular risk; in fact, the actual risk
is lower than with comparators, although differences do
not reach statistical significance. In fact, available data
do not rule out the possibility of an increase of cardio-
vascular risk up to 28%, or of a reduction up to 54%. It
should be considered that the duration of the available
trials (up to one year) is insufficient to detect any effect of
treatment (either detrimental or beneficial) on
atherogenesis.
The addition of unpublished trials does not substantially
modify the estimates of efficacy of DPP-4 inhibitors.
However, the retrieval of unpublished, but publicly dis-
closed, information allowed the identification of some
potentially interesting phenomena, such as cases of severe
hypoglycemia with DPP-4 inhibitor monotherapy, which
could not be detected in published papers.
Table 4 Adverse events in individual studies included in the meta-analysis.
Study (Ref.) Any Hypos
(n, ID/C)
Severe Hypos
(n, D/C)
Nausea
(n, D/C)
>Vomiting
(n, D/C)
Diarrhea
(n, D/C)
Nasopharyng.
(n, D/C)
Urinary infect.
(n, D/C)
CVD
(n, D/C)
Death
(n, D/C)
Any AEs
(n, D/C)
DPP-4 inhibitors
Vildagliptin
Pan [33] 0/0 0/0 NR NR 11/6 18/14 NR 3/1 0/0 154/113
Schweizer [28] 2/1 0/0 17/26 11/11 31/66 50/24 NR 0/2 2/2 364/190
Rosenstock [34] 1/0 0/0 NR NR NR 31,718 NR NR 1/0 282/152
2329 [14] NR NR NR NR NR NR NR NR 1/0 89/25
Bolli [21] 1/0 0/0 NR NR 1078 12/13 NR 2/2 0/0 177/158
Rosenstock [35] 1/0 0/0 NR NR NR 4/6 NR NR NR 78/83
1/0 0/0 NR NR NR 8/6 NR NR NR 141/83
Dejager [36] 3/0 0/0 7/6 NR 11/5 40/13 NR 5/0 0/0 313/97
Scherbaum [37] 0/1 0/0 NR NR NR 4/3 NR NR 0/1 28/28
Mari [38] 0/0 0/0 NR NR NR 16/13 NR 5/2 0/1 114/109
Scherbaum [39] 0/0 0/0 NR NR NR 16/13 NR NR 0/1 114/109
Pratley [27] 1/0 0/0 1/1 NR NR NR NR 0/0 0/0 39/20
Pi-Sunyer [40] 0/0 0/0 NR NR NR 1973 NR NR 0/0 150/53
Ristic [41] 14/3 NR 5/3 NR 5/3 15/5 NR 0/1 0/0 126/33
1202 [14] NR NR NR NR NR 41/18 NR 0/1 0/0 136/53
Ahren [42] 2/0 0/0 0/0 NR NR 2/6 1/3 0/0 0/0 29/28
Bosi [22] 1/1 0/0 13/9 NR 11/10 31/13 1/0 4/4 0/0 231/115
Garber [43] 2/3 0/0 10/4 NR NR NR 11/2 1/1 0/0 160/77
Garber [19] 8/1 0/1 9/6 3/6 9/8 18/4 NR NR 0/0 226/113
1302 [14] NR NR NR NR NR 14/14 NR 0/0 0/0 61/57
Fonseca [20] 33/45 0/4 8/4 NR 8/3 NR NR 0/1 1/1 117/133
1303 [14] NR NR NR NR 7/0 42/20 NR 0/0 0/0 108/41
D’Alessio [44] 0/0 0/0 NR NR NR NR NR NR NR NR
Sitagliptin
PN-036 [15] NR NR 0/2 1/0 2/4 NR NR NR 0/0 96/214
Scott [45] 1/1 0/0 1/1 1/1 3/3 4/3 NR 1/0 0/0 37/38
1/2 0/0 1/2 1/1 3/1 4/3 NR 1/0 0/0 37/28
PN-035 [15] NR NR NR NR NR NR NR NR 2/2 NR
Nauck [17] 29/187 1/7 15/16 5/9 34/32 60/42 31/15 0/3 1/2 419/444
PN-028 [15] NR NR NR NR 6/5 NR 3/2 5/0 3/0 NR
Scott [18] 12/21 3/1 NR NR NR NR NR 4/2 3/1 284/77
12/3 3/0 NR NR NR NR NR 4/0 3/0 284/67
Nonaka [46] 0/0 0/0 NR NR NR NR NR 0/1 0/0 44/49
Hanefeld [16] 5/0 1/0 NR NR NR 33/2 NR 3/0 0/0 201/38
Raz [47] 5/0 0/0 5/0 1/1 11/6 13/0 10/3 3/0 0/0 194/57
Goldstein [23] 1/1 NR 2/2 0/1 5/7 NR NR NR 0/1 96/89
Rosenstock [35] 2/0 0/0 2/0 1/1 3/2 NR NR 0/0 0/0 84/93
Hermansen [24] 27/4 0/0 1/1 3/1 3/6 NR NR NR 1/0 132/103
Goldstein [23] 6/3 NR 22/24 11/6 40/35 NR NR NR 1/0 225/214
Charbonnel [48] 6/5 0/0 6/2 5/2 12/6 19/8 11/3 2/0 1/0 262/128
Aschner [49] 5/2 0/0 15/3 5/3 21/6 32/12 13/7 3/3 0/0 317/167
Raz [50] 1/0 0/0 2/2 0/1 6/5 7/7 4/3 0/1 0/1 55/56
PN-040 [15] NR NR NR NR NR NR NR NR 1/0 82/27
PN-044 [15] NR NR NR NR NR NR NR NR 0/0 NR
Saxagliptin
Rosenstock [51] 0/0 0/0 12/5 NR NR 16/5 19/5 NR 0/0 215/53
Hypos: hypoglycemia; n: number; ID/C: investigational drug/comparator; nasopharyng.: nasopharyngitis; infect.: infections;
CVD: cardiovascular disease; and NR: not reported.
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recognized and considered when interpreting the results.
The analysis was performed on summary data, therefore
lacking the accuracy of assessment which can be obtained
when using patient-level data. For the very same reason,a time-to-event analysis for categorial outcomes (including
cardiovascular events) could not be performed; the
proportion of patients experiencing at least one event
during the trial, which was used for meta-analysis,
approximates the actual incidence of events only if this
Table 5 Selected adverse events during treatment with DPP-4 inhibitors.
Adverse event # Cases/# Patients # Trialsa MH-OR [95% CI] p
ID C
Nausea
DPP-4 Inhibitors 153/5795 119/3906 21 0.77 [0.57; 1.04] 0.09
Vildagliptin 70/2102 59/1014 8 0.63 [0.38; 1.07] 0.08
Sitagliptin 71/3689 55/2892 12 1.03 [0.71; 1.51] 0.86
Saxagliptin 12/271 5/67 1 e e
Vomiting
DPP-4 Inhibitors 47/4575 44/3119 14 0.73 [0.48; 1.12] 0.15
Vildagliptin 14/810 17/417 2 0.40 [0.19; 0.83] 0.014
Sitagliptin 33/3765 27/2702 12 1.02 [0.61; 1.69] 0.93
Saxagliptin e e e e e
Diarrhea
DPP-4 Inhibitors 249/6318 227 22 0.80 [0.56; 1.15] 0.23
Vildagliptin 103/2909 109/478 13 0.72 [0.74; 1.20] 0.34
Sitagliptin 146/3409 118/2641 9 0.98 [0.76; 1.26] 0.87
Saxagliptin e e e e e
Nasopharyngitis
DPP-4 Inhibitors 566/7589 282/4132 27 1.04 [0.60; 1.68] 0.59
Vildagliptin 373/4688 200/2442 18 0.93 [0.77; 1.12] 0.42
Sitagliptin 168/2901 77/1690 8 1.43 [1.07; 1.91] 0.017
Saxagliptin 16/271 5/67 1 e e
Urinary infections
DPP-4 Inhibitors 104/2938 43/1904 10 1.36 [0.94; 1.97] 0.10
Vildagliptin 13/685 5/379 3 1.30 [0.30; 5.71] 0.73
Sitagliptin 72/2253 33/1525 6 1.44 [0.94; 2.19] 0.09
Saxagliptin 19/271 5/67 1 e e
Upper respiratory infections
DPP-4 Inhibitors 302/4902 173/3229 18 0.91 [0.74; 1.12] 0.40
Vildagliptin 150/2885 96/1475 11 0.82 [0.62; 1.10] 0.18
Sitagliptin 131/2017 73/1754 6 0.99 [0.74; 2.32] 0.96
Saxagliptin 21/271 4/67 1 e e
Other infections
DPP-4 Inhibitors 178/3059 118/1538 13 0.70 [0.55; 0.90] 0.005
Vildagliptin 110/1618 63/944 8 0.68 [0.47; 0.99] 0.042
Sitagliptin 62/1441 55/594 5 0.72 [0.52; 1.01] 0.056
Saxagliptin e e e e e
ID: interventional drug; and C: comparator.
a Trials with 0 events or without any information are not included.
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tion of the trial. Furthermore, the number of subject
studies and the duration of trials performed is insufficient
to draw any definitive conclusion on the long-term cardio-
vascular safety of DPP-4 inhibitors.
In conclusion, DPP-4 inhibitors are effective in reducing
HbA1c and post-prandial glucose; when used as an add-on
to metformin, they show a medium-term efficacy on HbA1c
similar to thiazolidinediones and marginally inferior to
sulphonylureas, with a reassuring short- and medium-term
safety profile. In fact, the hypoglycemic risk is low, and
there is no evidence of detrimental effects on cardiovas-
cular disease. In comparison with sulphonylureas or insulin,
which have been proposed as first-choice agents in patients
failing with metformin [4], DPP-4 inhibitors exhibit, at least
in the short- and medium-term, a lower hypoglycemic riskand a more favorable action on body weight, at the price of
a somewhat smaller efficacy and higher cost. The choice of
the drugs to be used as add-ons to metformin in mono-
therapy failure largely depends on the relative weight
attributed to each of these three components (safety,
efficacy on HbA1c and cost).
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